Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rollover study of ruxolitinib or ruxolitinib + panobinostat for patients benefiting from prior Novartis/Incyte trials
jRCT2080225007Phase 4Completed
- Sponsor
- Novartis
- Start
- Jan 2020
- Modality
- Small Molecules
01
Overview
Phase 4, open-label trial of ruxolitinib and panobinostat in myelofibrosis (MF), polycythemia vera (PV), graft-versus-host disease (GVHD) and 1 more (2 arms), sponsored by Novartis. Started Jan 2020; status: completed.
02
Drugs
ruxolitinibpanobinostat
03
Conditions
myelofibrosis (MF)polycythemia vera (PV)graft-versus-host disease (GVHD)Myeloproliferative neoplasm unclassifiable (MPN-U)
Beyond the preview
Go deeper on jRCT2080225007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225007.